PYPD is expected to report earnings to fall 19.66% to -90 cents per share on May 07
Q1'25
Est.
$-0.91
Q4'24
Missed
by $0.22
Q3'24
Missed
by $0.22
Q2'24
Beat
by $0.05
Q1'24
Beat
by $2.78
The last earnings report on February 12 showed earnings per share of -112 cents, missing the estimate of -91 cents. With 6.22K shares outstanding, the current market capitalization sits at 30.47M.
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes